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Abstract: This literature review summarizes the existing research examining the CNS penetration
effectiveness (CPE) score and neurocognitive outcomes (i.e., neuropsychological assessment and
neurocognitive screening) in HIV+ individuals. Despite the effectiveness of Combined Antiretroviral
Therapy (CART) in reducing mortality and morbidity in HIV and controlling viral replication, HIV
often persists in the Central Nervous System (CNS), and rates of neurocognitive impairment remain
higher than predicted in the post-CART era. The CPE score was developed to rank antiretroviral
regimens on their ability to penetrate the CNS and potency in inhibiting the virus, and it has been
examined in relation to neurocognitive functioning for over a decade. Based on the results of
23 studies, we conclude that CPE is not as strongly associated with neurocognitive outcomes as
initially hypothesized, although higher CPE ARV regimens may be associated with modest, improved
outcomes in global neurocognitive functioning, and to a lesser extent attention/working memory
and learning/memory. Conclusions, however, are limited by the heterogeneity in study design and
methods, and the lack of a more recent CPE metric update. It is recommended that future research
in this area employ comprehensive, standardized neuropsychological test batteries and examine
domain-level performance, and use the newer 2010 CPE metric, although an updated CPE ranking is
urgently needed.
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1. Introduction
Antiretroviral (ARV) medications are first-line treatments for HIV+ individuals and
are key to managing HIV disease. ARV medications reduce viral replication that would
otherwise allow the disease to rapidly proliferate throughout the body. They have greatly
improved morbidity and mortality rates among individuals with HIV/AIDS, particularly
since the inception of highly active antiretroviral therapy (HAART) in 1996, now referred to
as Combined Antiretroviral Therapy (CART) [1,2]. CART combines multiple antiretroviral
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medications in one regimen and has been found to provide more potent, effective control of
the HIV virus than earlier, single-medication regimens. Before the advent of antiretroviral
medications, high viral loads and CD4 counts were associated with more frequent and
severe disorders; CART has helped to reduce the incidence of these conditions and improve
survival rates [3]. With CART, life expectancy among HIV+ individuals has increased by
over 20 years, and is continuing to increase over time [4]. Overall, improvements in the
pharmacological treatment for the human immunodeficiency virus (HIV) has drastically
changed the face of the HIV epidemic over the last few decades, transforming a once fatal
disease into a chronic illness.
Despite the effectiveness of CART in suppressing the HIV virus, medications cannot
completely eradicate the virus from the system and there is still no cure for this disease. The
HIV virus has an affinity for the central nervous system (CNS) [5], and studies have shown
that even with stable CART treatment, latent viral reservoirs persist in the CNS, including
the cerebrospinal fluid or CSF [2]. The presence of the virus in the brain can trigger a cascade
of events implicated in neuropathogenesis. These processes particularly affect frontostriatal
and subcortical circuitry, and the resulting neuropsychological and functional declines
are characterized as HIV-Associated Neurocognitive Disorders (HAND) [6–11]. Although
patterns of neuropsychological impairment are variable, deficits are often reported in
processing speed, attention, executive functioning, learning, and memory [6,12–17].
Even in the post-CART era rates of cognitive impairment remain high, with an estimated 50% of HIV+ individuals exhibiting HAND [6] including those with long-standing
viral suppression [17]. While rates of severe impairment associated with uncontrolled HIV
proliferation (e.g., HIV-associated Dementia (HAD)) have decreased, mild and moderate
forms of neuropsychological impairment have increased. Thus, neurocognitive decline
remains a critical issue in this population [18–21]. It is unclear why cognitive impairments
persist. Some studies have found that comorbid conditions such as vascular disease may
more strongly predict HAND diagnosis than HIV RNA concentrations [22]. One question
that surfaced is whether and how newer and more potent HIV antiretroviral medications
affect the brain. Antiretroviral CNS neuropenetrance—also referred to as “CNS neuropenetrance”, which includes a medication’s ability to cross the blood–brain barrier (BBB) and
penetrate the CNS—has been considered. Some HIV medications may be better at controlling the virus in the periphery than in the CNS, which is referred to as lower CNS
efficacy. While many have suggested that ARV medications with higher neuropenetrance
may protect the brain by more potently inhibiting the virus, some have questioned whether
more neuropenetrant medications may be neurotoxic, thereby further damaging the brain.
This has led to increased interest in the dynamics of CART pharmacology, including differences in blood–brain-barrier (BBB) penetration, and to the methods for classifying ARV
neuroactivity or neuropenetrance.
Currently, the most widely used method for classifying antiretroviral neuropenetrance
is the CNS penetration effectiveness (CPE) rank. Developed by Letendre and colleagues,
this hierarchical scheme numerically ranks antiretroviral regimens on their ability to penetrate the CNS. Numerical rankings are derived from pharmacological data, particularly
the pharmacokinetic, chemical, and pharmacodynamic properties of each ARV medication [23,24]. Lower CPE medications are thought to less potently inhibit the virus and allow
larger viral reservoirs to remain in the brain, leading to more viral replication. Research
has shown that higher CPE medications have been associated with lower viral load in
both cerebrospinal fluid (CSF) and plasma [23,25,26]. CPE has also been associated with
structural changes in the brain; for example, CPE 2010 score was specifically associated
with reduced gray matter integrity among patients in the very early stages of HIV (i.e., less
than 1 year duration) [27]. Although CPE score has been calculated and examined in HIV
research for over a decade, there is currently no review of the literature examining the CPE
metric and neurocognitive outcomes (i.e., neuropsychological assessment and cognitive
screening) in HIV+ individuals. Therefore, the purpose of this review is to summarize the
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existing literature and provide conclusions about the evidence regarding CPE score and
neurocognitive outcomes among adults living with HIV.
As described above, the CPE rank is a summary score developed by Letendre and
colleagues that hierarchically ranks HIV medications on their CNS penetrance or neuropenetrance based on pharmacological data and physical properties. The CPE metric was
first described in 2008 [23] in which medications were assigned a 0–2 score, with higher
scores reflecting greater neuropenetrance. Specifically, scores of 0 were defined as no or
low neuropenetration, scores of 0.5 suggest an intermediate-level of neuropenetration,
and scores of 1.0 reflect adequate or good neuropenetration. This was later revised, and
the 2010 CPE metric updated by Letendre and colleagues assigns each HIV medication a
1–4 integer score, with higher scores again reflecting greater neuropenetrance [24]. This
update provides CPE ranks for a wider variety of HIV medications, including newer
medications, and also allows for finer distinctions between degrees of neuropenetrance
through its increased range. Per convention, scores are summed for all HIV medications in
a patient’s regimen [25]. The CPE scores for commonly prescribed ARV medications, for
both the 2008 and 2010 CPE metrics (see Supplementary Materials, Table S1). For a more
detailed description of the development and update of the CPE rank, please see [23,24].
In comparing the two ranking systems, Ciccarelli and colleagues [28] found that
the 2010 ranking system is more effective and associated with better neurocognitive performance. Similarly, CPE 2010 was significantly associated with ventricular atrophy in
HIV+ individuals when CPE 2008 was not [29]. More recent studies typically use the updated 2010 metric; however, CPE 2008 has historically been investigated more frequently.
Studies using either CPE 2008 or CPE 2010 were included in this review. For each article
reviewed, the CPE ranking used, study and sample characteristics, and key methodology
are presented in our summary table (see Supplementary Materials, Table S2). Results and
conclusions are described in the text below.
2. Materials and Methods
Search Strategy and Selection Criteria
We first identified studies that cited either 2008 or 2010 CNS Penetration Effectiveness
score [23,24], and these were examined for inclusion. Second, literature searches were
conducted using the following search terms in PubMed, Google Scholar, and PsycINFO:
“CNS Penetration Effectiveness”, “CNS Neuropenetrance”, “CPE score”, “ARV neuropenetrance”, “antiretroviral neuropenetrance”, “ARV efficacy” and “antiretroviral efficacy”.
These search terms yielded a total of 3899 articles. From these results, studies that did
not examine HIV+ adults, antiretroviral neuropenetrance measures (i.e., CPE 2008 or CPE
2010 score), and neurocognitive outcomes were excluded. Only studies that specifically
examined the relationship between CPE 2008 or CPE 2010 scores and neurocognitive performance (i.e., neuropsychological tests or cognitive screenings) were included. These articles
were independently reviewed and summarized by at least two study authors (MA, KA,
MG, and/or AA). Study quality was determined by the first author using the Joanna Briggs
Institute (JBI) Critical Appraisal Checklist for Systematic Reviews and Research Syntheses
(JBI, 2020). Ultimately, this yielded a total of 23 studies which were included in this review.
3. Results and Discussion
The following review summarizes the existing literature on the neuropenetrance of
HIV medication regimens as assessed by CPE score and observed neurocognitive outcomes
in HIV. First, we provide background on how CPE affects plasma and CSF viral load
and the literature that has examined these relationships in patients that are initiating
HIV medication and patients on existing ARV regimens. Next, we focus specifically
on the literature examining the relationship between CPE and neuropsychological test
performance or neurocognitive screening, considering global neurocognitive outcomes first
and then discussing the available results by traditional neuropsychological domain. Finally,
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we provide our overall conclusions about the CPE literature in this area and some general
recommendations for future research and practice.
3.1. CPE and Viral Load in Plasma and CSF
The main goal of antiretroviral therapy in patients with HIV, particularly combined
antiretroviral therapy (CART), is to suppress viral replication and reduce the amount of
the virus in both plasma and cerebrospinal fluid (CSF). By suppressing viral replication,
it is thought that CART reduces the amount of HIV in the brain, which in turn reduces
damage to the brain and central nervous system that would result in neurocognitive
dysfunction [30]. Therefore, it is expected that medications with higher CPE rank would
more effectively reduce the amount of the virus in plasma and CSF. CSF measurements
are used as proxies for ARV concentrations in the brain, since more direct measurement in
tissue can only be performed post-mortem; however, it is important to note that CSF and
brain concentrations may differ, and in fact, some studies suggest that CSF measurements
may underestimate concentrations in the brain [31–33]. This is a limitation of both CSF
measurement as well as the CPE metric.
Prior to the development of the CPE score, researchers suggested that the neuropenetrance of HIV medications may be important. Sacktor and colleagues [30] studied
plasma and CSF viral loads at baseline and follow-up in groups with single and multiple CNS-penetrating ART medications, and found that adding at least one antiretroviral
mediation with good CNS penetration can aid in suppressing the virus both in CSF and
plasma [30]. When this was initially examined using the CPE ranking system, some studies did not find these effects in ARV-naive patients. Tozzi and colleagues [34] found no
association between CD4 cell counts, plasma viral loads, and CPE scores. Similarly, Marra
and colleagues [35] found no significant association between CPE rank, number of ARV
medications, and viral suppression. In a study specifically comparing ARV-naïve and
ARV-experienced patients, they found that ARV-naïve patients had greater odds of plasma
and CSF viral suppression compared to ARV-experienced patients. In terms of CPE rank
and suppression, there were greater odds of CSF HIV RNA suppression when the 2008
CPE score was greater than or equal to two; however, there was no association between
plasma viral suppression and CPE rank.
However, later research has shown that ARV regimens that are modified in
ARV-experienced HIV patients may provide benefits. A study specifically examining
2008 CPE ranks and viral load found that CSF HIV RNA was significantly lower in those on
stable ARVs compared to those not on ARVs [36]. Additionally, they found that higher CPE
scores were significantly correlated with improved CSF viral suppression. Similarly, Cusini
and colleagues [37] found that higher CPE scores were associated with better HIV RNA
viral suppression using both 2008 and 2010 CPE ranks. They reported that a minimum
threshold score of 2 under the 2008 CPE rankings and a minimum threshold score of 7 under
the 2010 CPE rankings achieved the most successful viral suppression [37].
For some patients with HIV, HIV RNA is detectable in the CSF even though plasma
viral suppression has been achieved, which is referred to as “CSF viral escape” [38]. It
is thought that between 4–20% of ARV-experienced HIV patients experience CSF viral
escape [38]. Even when plasma viremia is suppressed by ARVs, HIV RNA may still
replicate if poor CSF penetration causes low concentrations of the medications in the
CSF, which can lead to drug resistance. It has been hypothesized that this could result
in neurological symptoms, even when plasma viral load is suppressed. Results suggest
that regimens with lower CPE scores may increase the likelihood of viral escape. Canestri
and colleagues [39] examined ARV-experienced patients with HIV-related neurological
symptoms who had discordant plasma and CSF RNA. ARV regimens were modified
based on drug resistance and that no patient had a CPE rank of less than two. Within
six weeks, they found neurological improvement, normalization of CSF cellularity and
protein levels, and undetectable HIV viral loads [39]. Over the course of a four-year followup, approximately 7% of patients experienced viral escape [38]. When CPE scores were
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adjusted for resistance mutations, adjusted CPE scores were lower in those experiencing
viral escape, although raw CPE scores between the viral escape and non-escape group
were not significantly different. Furthermore, differences between plasma and CSF viral
load concentrations suggest that HIV compartmentalization can occur [40]. Viral sequences
may become genetically distinct across tissue compartments in the CNS and periphery,
and differences in the concentration and movement of ARV medications in the CNS may
be important to address. ARV medications may insufficiently target particular sequences
and/or compartments, and low CPE medications may be more likely to do so, but this
should be investigated further.
Moreover, although antiretroviral inhibitory concentrations have been found to correlate with CPE scores, variability in CSF viral load across individuals has still been observed,
suggesting that some patients may receive a greater benefit from ARV medications than
others [41,42].
3.2. CPE and Neurocognitive Functioning
While previous studies have broadly reported associations between higher CPE scores
and improved CSF and plasma viral suppression, studies examining the association between CPE and neurocognitive outcomes have had more variable results. Below, we
summarize findings from studies that explored the relationship between CPE rank and
neurocognitive functioning, organized by neurocognitive domain. Of note, no studies
specifically examined visuospatial functioning (although some included visuospatial measures in their global neurocognitive summary scores), so this domain is not discussed.
3.2.1. Global Functioning
Global neurocognitive functioning typically provides a summary of neurocognitive
abilities by averaging data obtained across several neurocognitive domains; this can vary
from a more comprehensive summary, obtained from several tests across all major neuropsychological domains (e.g., learning/memory, attention, processing speed, executive
functioning, motor functioning, and verbal functioning), to a less comprehensive summary,
examining one or a few tests across a few traditional domains. In the extant literature
examining CPE and neurocognitive performance, most studies have focused on global
functioning and have used abbreviated screening batteries, which is a limitation. Additionally, some studies examine global neurocognitive performance as a continuous measure
while some use these measures to provide HAND diagnoses, typically employing the
Frasati criteria [6]. However, as a statistically derived approach, some have criticized
the Frascati criteria, suggesting that the recommended one standard deviation cut-off for
impairment may lead to a small percentage of false positives in HAND diagnoses [43],
although others have empirically supported it for its validity and sensitivity [44]. Of the
15 studies examining global functioning, generally, the weight of the evidence seems to
suggest a modest relationship between CPE and global neurocognitive performance.
First, the evidence from cross-sectional research is somewhat more consistent. In
a large sample of relatively healthy and cognitively intact HIV+ individuals (i.e., about
75% of the sample performed within one standard deviation of the mean) on stable ARV
treatment for at least 90 days, higher CPE 2010 score was significantly associated with
lower global deficit score (i.e., better global neurocognitive functioning) based on a screening of neuropsychological tests. The likelihood of neurocognitive impairment decreased
by 17% for each point increase in CPE 2010 score [45]. In a study comparing HIV-RNA
suppressed patients with ARV-naive patients commencing their initial regimens, 2010 CPE
scores were associated with neurocognitive impairment in patients with nadir CD4 below
200; specifically, immunocompromised patients with lower CPE scores were more likely
to be diagnosed with a HAND than those with higher CPE scores. Global functioning
in this study, however, was based on a 4-test screening battery of motor and processing
speed tests. Among all patients, those with CPE scores less than seven had worse neuropsychological functioning, although this only reached trend-level [46]. Using a more
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comprehensive neuropsychological battery, including all traditional neuropsychological
domains, 2010 CPE scores were independently associated with better neurocognitive performance, and patients with higher 2010 CPE scores were less likely to be diagnosed with
HAND, although this relationship was not observed for 2008 CPE scores [28]. Fabbiani
and colleagues [47] conducted a retrospective examination of HIV+ individuals who had
received several neuropsychological tests during outpatient care, and obtained data on
viral resistance, which would impact the effectiveness of the ARV regimen. Initially, they
found no relationship between CPE 2010 scores and global neuropsychological functioning,
but after correcting for viral resistance, they found that higher CPE scores were associated with significantly lower risk of global neuropsychological impairment [47]. Finally,
higher CPE 2008 score was significantly associated with better global neuropsychological
functioning based on a comprehensive battery at 40-month follow-up, but not at 20-month
follow-up, in a sample of HIV+ individuals with cognitive symptoms or CD4 count below
200 [34]. Furthermore, these associations were found at both 20- and 40-month visits
among patients who were cognitively impaired and among those who were virally suppressed. Simioni and colleagues [17] examined HAND diagnoses based on the results of a
neurocognitive screening in HIV+ individuals with suppressed viral load who reported
cognitive complaints. In this study, CPE 2008 score did not significantly differ between
those who received any level of HAND diagnosis and those who did not. However, a
trend was observed such that patients with CPE scores of at least 2 were less likely to be
given a HAND diagnosis involving functional impairment compared to patients with lower
CPE scores [17]. Wright and colleagues [48] found no association between average global
neuropsychological performance and 2008 CPE scores among HIV+ individuals with CD4
counts higher than 350, although this was based on z-scores obtained from a 5-test screening
battery focusing on motor functioning and processing speed. Similarly, based on a 4-test
screening battery, global NP functioning was not associated with 2010 CPE scores when
examined categorically (i.e., CPE < 7 vs. CPE ≥ 7) or when examined continuously [49].
Finally, among older HIV+ individuals on stable CART for at least 6 months, CPE 2010
was not significantly associated with global neurocognitive performance, although a different estimate of ARV effectiveness in inhibiting monocytes (i.e., monocyte efficacy) was
significantly associated [50]. Monocyte efficacy is linked to, and significantly associated
with CPE, but has not been investigated in other studies. Participant age, however, may
be important; the ability to absorb, distribute, metabolize, and excrete medications may
become less effective, which may affect the relationship between CPE and neurocognitive
functioning. Additionally, older HIV+ patients tend to have more comorbidities, and may
be taking a larger number of medications overall, which increases the likelihood of side
effects and other interactions [51].
Several longitudinal studies have also found higher CPE to be associated with improved global neurocognitive functioning. Among HIV+ individuals assigned to a CART
regimen (i.e., ARV-naive individuals or those experiencing treatment failure), CPE 2008
scores ≥ 2 predicted improvement in global cognitive functioning over 48 weeks, with the
most marked improvement seen at 12 weeks. In multivariate analyses, only higher CPE
and worse baseline NP were significant predictors of NP improvement, while longitudinal
decreases in viral load were not [52]. Similarly, Vassallo et al. [53] found that patients
with lower CPE 2010 scores at baseline were significantly more likely to be diagnosed
with HAND based on neuropsychological test performance. At 2-year follow-up, patients
with lower CPE scores were more likely to have cognitively deteriorated, meaning that
they were diagnosed with HAND when they had not been at baseline, or had progressed
to a more severe HAND diagnosis. In a sample from a large clinical trial of HIV+ individuals with suppressed HIV viral load, better global neuropsychological scores were
associated with higher 2008 CPE rankings in participants taking more than three ARV
medications, but not in patients taking less than three ARVs, even after accounting for
numerous potential covariates [54]. A small sample of HIV+ individuals experiencing at
least mild cognitive symptoms who were on CART with undetectable viral load for at least

Viruses 2022, 14, 1151

7 of 17

one year received ARV intensification, meaning that ARV medications were changed or
added to their regimen in order to increase the overall regimen CPE score [55]. CPE scores
were adjusted for drug resistance and increased an average of 4 points across the sample.
Participants received a comprehensive neuropsychological battery used to generate HAND
diagnoses and global deficit scores (GDS), and after 48 and 96 weeks, higher CPE score was
associated with greater improvement in neurocognitive functioning. Participants, however,
were not randomized and there was no comparison group (i.e., participants not receiving
ARV intensification). Patients also had very lengthy past treatment histories and exhibited
significant medication resistance.
Other longitudinal studies have failed to replicate this relationship, although several
also had some noteworthy limitations. In a randomized clinical trial, HIV+ participants
who were assigned to the higher CPE medication arm (based on CPE 2008 score) showed
a greater reduction in global cognitive deficits over the course of 16 weeks, based on a
comprehensive neuropsychological battery, although the difference between groups was
not statistically significant [56]. This effect was most pronounced among individuals
with plasma HIV viral load suppression and those who were previously ARV-naive, but
again, not statistically significant. However, the authors note that conclusions were limited
by the fact that the RCT was discontinued early due to limited recruitment, cognitive
changes were assessed over just 16 weeks, and treatment groups differed on several key
characteristics that may affect the results (e.g., nadir CD4, hepatitis co-infection, plasma
HIV viral load). An evaluation of the large-scale multisite CHARTER study baseline cohort
showed that CPE 2008 score did not emerge as a significant, independent predictor of
global deficit score, derived from a comprehensive neuropsychological test battery, when
included in a multivariate logistic regression [20]. In a subset of the CHARTER longitudinal
sample, HIV+ individuals were classified based on whether they improved, declined, or
remained stable based on global neurocognitive performance over an average of 35 months,
obtained from a comprehensive NP battery applying regression-based norms. There were
no significant differences observed between these groups on CPE 2008 score [57]. Marra
and colleagues [35] found no significant relationship between impaired global cognitive
scores on a short screening of neurocognition and CPE 2008 score at baseline. Unexpectedly,
participants with a CPE score of ≥2 had lower global neurocognitive scores over the course
of the one-year study. It was suggested that worse cognitive performance in participants
with better neuropenetrance could reflect the neurotoxic effects of high CPE medications
in participants with advanced HIV disease [35], a hypothesis that has not yet seen further
empirical support. Additionally, Cross and colleagues [58] did not find differences in
global cognitive performance, based on a comprehensive neuropsychological test battery,
between patients with high and low 2010 CPE score ARV regimens. Interestingly, however,
South Africa (where this study was conducted) changed their recommended first-line ARV
medications from a higher to a lower CPE regimen, which may be an important difference
between this and other samples.
Although findings have differed across studies, generally, there seems to be a modest
relationship between higher CPE scores and better global neurocognitive performance.
Studies that employed the newer, 2010 CPE ranking system and those employing comprehensive neuropsychological batteries were more likely to report significant findings,
suggesting that methodology may be at least one important factor. Differing patient
characteristics, including length of time on ARV therapy, virological characteristics and
immunological status, are all further complicating factors.
3.2.2. Attention/Concentration and Working Memory
In contrast to global functioning, fewer studies have specifically examined domain
level neuropsychological or neurocognitive performance. The five studies that have examined attention, working memory, and/or concentration and CPE score are somewhat
equivocal, but suggest that there may be a modest relationship between these variables.
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A higher CPE 2008 score was significantly associated with better concentration at both
20- and 40-month follow-up, in a sample of HIV+ individuals with cognitive symptoms or
CD4 count below 200 [34]. This relationship was also significant among those who were
cognitively impaired (at 20- and 40-month visit) and those who were virally suppressed
(at 20-month visit). In a large cohort of cognitively intact HIV+ individuals on stable ARV
treatment for at least 90 days, CPE 2010 score was significantly associated with better
working memory (i.e., WAIS-R Digit Symbol; [45]. Ciccarelli and colleagues reported that
better performance on one measure of attention/working memory (i.e., double barrage
test) was associated with higher 2010 CPE score [28], although this is a less commonly
used neurocognitive measure. However, in a retrospective study, CPE 2010 scores were
not associated with attention (i.e., digit span subtest), even after correcting for viral resistance, in HIV+ patients receiving routine outpatient care [47]. Among a small cohort of
HIV+ individuals with undetectable viral load on stable CART, CPE 2008 score did not correlate with attention and working memory (i.e., Digit Symbol Substitution Task (DSST) and
WAIS-IV Letter-Number Sequencing) at baseline or at 2-year follow-up [59]. However, this
virologically well-controlled sample also did not show significant neurocognitive decline
over time, and neuropsychological performance was not associated with other virological
characteristics. The authors note that CPE range was also limited, with most participants
receiving relatively neuropenetrant medications.
3.2.3. Processing Speed
Out of six studies that have specifically examined the domain of processing speed, the
evidence is more consistent. There does not appear to be a significant relationship between
processing speed and CPE score.
Among HIV+ individuals exhibiting cognitive symptoms or immunosuppression
(e.g., CD4 count below 200), higher CPE 2008 scores were significantly associated with
better processing speed at 20- and 40-month follow-up visits [34]. This relationship was
also significant among those who were cognitively impaired (at 20- and 40-month visit)
and those who were virally suppressed (at 20-month visit). However, this is the only
study in our review that reported such a relationship. No significant differences in CPE
2008 scores were found between HIV+ patients classified as cognitively impaired (i.e.,
performance below the 10th percentile on at least three tests compared to HIV-negative
control group) and those who were not impaired on the WAIS-III Digit Symbol Coding
subtest [60]. The potential limitations of the definition of impairment were described above.
A retrospective study showed that CPE 2010 scores were not associated with processing
speed (i.e., WAIS Digit Symbol), even after correcting for viral resistance, in HIV+ patients
receiving routine outpatient care [47]. Similarly, CPE 2010 score was not significantly
associated with processing speed (i.e., WAIS Digit Symbol) in a large cohort of cognitively
intact HIV+ individuals on stable ARV treatment for at least 90 days [45]. In a crosssectional study employing a screening of neuropsychological functioning, processing speed
(i.e., Trailmaking Test-Part A or TMT-A) was not associated with 2010 CPE scores when
examined categorically (i.e., CPE < 7 vs. CPE ≥ 7) or when examined continuously [49].
Finally, among HIV+ individuals with undetectable viral load on stable CART, CPE 2008
score did not correlate with processing speed (i.e., Trailmaking Test-Part A or TMT-A) at
baseline or at 2-year follow-up [59]. As mentioned above, neuropsychological performance
was also not associated with other virological characteristics, and participants tended to be
prescribed high CPE regimens.
3.2.4. Learning/Memory
The relationship between CPE score and learning and/or memory, measured through
either verbal and/or visual tests, has been examined in 10 studies. Although some studies
did find a significant relationship between learning/memory and CPE score, generally, the
relationship is not consistently reported. Studies that did, however, employed the newer,
2010 CPE score.
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In a large group of cognitively intact HIV+ individuals on stable ARV treatment for at
least 90 days, CPE 2010 score was significantly associated with better learning/memory
(i.e., HVLT-R and BVMT-R) [45]. Ciccarelli and colleagues [28] similarly found that participants with higher 2010 CPE scores were significantly less likely to be impaired on verbal
memory (i.e., Rey Auditory Verbal Learning Test, or RAVLT), and notably, no significant
association was found for 2008 CPE scores. No relationships were reported for measures of
visual memory (i.e., Rey Complex Figure Test or RCFT) in this study; however, in another
study, Keutmann and colleagues found that higher 2010 CPE scores were associated with
better visual memory (i.e., BVMT-R) performance [61]. Of note, this measure employed
by Keutmann and colleagues is less confounded by executive functioning than the RCFT,
which was used by Ciccarelli. In another study examining RAVLT, CPE 2010 scores were
not associated with verbal memory (i.e., RAVLT) in HIV+ patients receiving routine outpatient care, although a trend was observed after correcting for viral resistance [47]. No
significant differences in CPE 2008 scores were reported between HIV+ patients who were
cognitively impaired and those who were not on a test of verbal memory (i.e., Botswana
Auditory Verbal Learning Test, BAVLT; Lawler et al., 2011). The cut-off used to determine
neurocognitive impairment, however, may have been overly conservative; the threshold
was defined as performance below the 10th percentile compared to an HIV-negative control
group. In a cross-sectional study employing a screening of neuropsychological functioning,
verbal learning (i.e., HVLT-R, which is the verbal analog to the visual BVMT-R) was not
associated with 2010 CPE scores when examined categorically (i.e., CPE < 7 vs. CPE ≥ 7)
or when examined continuously [49]. CPE 2008 score was not significantly associated with
better memory performance at either 20- and 40-month visit in a sample of HIV+ individuals with cognitive symptoms or CD4 count below 200 [34], although the specific memory
measure used was not reported. In a small sample, CPE 2008 score was not significantly
associated with performance on a brief, less commonly used screening of memory (i.e.,
the “5 words” test) among HIV+ individuals on a stable CART regimen for 4–7 years [62].
Among HIV+ individuals with undetectable viral load on stable CART, CPE 2008 score
did not correlate with verbal learning and memory (i.e., HVLT-R) at baseline or at 2-year
follow-up [59]. The limitations of this study were mentioned above, but briefly, neuropsychological performance was also not associated with other virological characteristics, and
participants tended to be prescribed high CPE regimens. Finally, no significant differences
were reported between participants with high vs. low 2010 CPE scores based on a median
split, although two less commonly used measures of procedural learning were employed
in this study (i.e., weather prediction and pursuit motor) [63].
3.2.5. Executive Functioning
Executive functioning has been examined in five studies. Similar to the findings
reported in several other domains, studies have generally have not reported a significant
relationship between CPE and executive functioning. Studies tended to include only
a single, brief screening of executive functioning, which may be insufficient given the
heterogeneity and complexity of this neuropsychological domain. Specifically, most studies
used a trailmaking-type test, which also overlaps significantly with other NP domains.
A higher CPE 2008 score was significantly associated with better mental flexibility
at both 20- and 40-month follow-up, in a sample of HIV+ individuals with cognitive
symptoms or CD4 count below 200 [34]. In a cross-sectional study employing a screening
of neuropsychological functioning, performance on a measure of executive functioning (i.e.,
TMT-B) was not associated with 2010 CPE scores when examined categorically (i.e., CPE < 7
vs. CPE ≥ 7) or when examined continuously [49]. Similarly, among HIV+ individuals with
undetectable viral load on stable CART, CPE 2008 score did not correlate with executive
functioning (i.e., TMT-B) at baseline or at 2-year follow-up [59]. As mentioned previously,
participants were generally on high CPE regimens and NP performance was not associated
with other virological characteristics. One study concluded that CPE 2008 scores were not
associated with performance on an executive function task (i.e., Color Trails 2; [60]. Finally,
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in a small sample, higher CPE 2008 score was associated with worse performance on a
short screening of executive functioning (i.e., Frontal Assessment battery) among HIV+
individuals on a stable CART regimen for 4–7 years [62].
3.2.6. Motor Functioning
Motor functioning has been examined individually in only 3 studies, making this the
least investigated domain in our review. It was not found to be significantly associated
with CPE. Notably, however, most studies that focused on global neurocognitive functioning included measures of motor functioning and tended to use the same, widely used
tests: either grooved pegboard [20,35,46,48,52,58] and/or finger tapping test [35,48,53,58].
Unfortunately, however, these studies did not examine CPE and motor functioning at the
domain level.
CPE 2010 scores were not significantly associated with motor functioning (i.e., grooved
pegboard) in HIV+ patients receiving routine outpatient care, although a trend was observed after correcting for viral resistance [47]. No significant difference in CPE 2008 scores
were found between HIV+ patients classified as cognitively impaired (i.e., performance
below the 10th percentile compared to HIV-negative control group) and those who were
not on grooved pegboard [60]. Finally, CPE 2008 score was not significantly associated with
motor functioning at either 20- and 40-month visits, although higher CPE 2008 score was
significantly associated with better motor functioning among those who were cognitive
impaired (at 20- and 40-month visit) and those who were virally suppressed (at 20-month
visit) [34].
3.2.7. Language/Verbal Functioning
Language functioning has been examined in four studies, none of which reported a
significant association with CPE score. Of note, all studies used screening of verbal fluency
to assess language/verbal functioning, and similar measures were employed across studies.
While these verbal fluency measures are often combined with other tests in comprehensive
batteries to examine attention/executive function, here, we will consider them in isolation
as measures of language/verbal functioning.
Verbal fluency (i.e., COWAT semantic fluency) was not associated with 2010 CPE
scores when examined categorically (i.e., CPE < 7 vs. CPE ≥ 7) or continuously [49]. CPE
2010 scores were not significantly associated with verbal fluency (i.e., COWAT letter fluency)
in HIV+ patients receiving routine outpatient care, even after correcting for viral resistance [47]. No significant difference in CPE 2008 scores were found between HIV+ patients
classified as cognitively impaired (i.e., performance below the 10th percentile compared
to HIV-negative control group) and those who were not on a measure of verbal fluency
(i.e., action fluency) [60]. Finally, among HIV+ individuals with undetectable viral load on
stable CART, CPE 2008 score did not correlate with verbal fluency (i.e., letter fluency and
action fluency) at baseline or at 2-year follow-up [59]. Overall, there is no evidence to date
of a relationship between language or verbal functioning and CPE.
3.3. Summary of Confounding Factors to Consider
There are numerous factors that may potentially limit the conclusions that can be
drawn from CPE and neurocognitive test performance based on their relationship with
these variables or the degree to which they vary across studies. To summarize, the following
confounds should be considered in examining and planning research in this area:

•

•
•
•

History of ARV experience (e.g., ARV naïve prior to study enrollment or not; duration
of ARV treatment; number of past ARV regimens, neuropenetrance of past ARV
regimens; adherence)
ARV drug resistance, inter-individual and intra-individual variability in CNS
ARV concentrations
ARV neurotoxicity, pharmacokinetics
HIV compartmentalization and distribution of medications in the CNS
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•
•
•
•
•
•
•

Study sample size and observed power
CPE score selected (e.g., 2008 vs. 2010) and cut-offs used
Cross-sectional vs. longitudinal design (including follow-up duration)
Years conducted (e.g., cohort effects, changes in medication prescribing practives)
Influence of demographic factors (e.g., age, gender, race/ethnicity) and existing comorbidities (e.g., vascular disease, hepatitis C, metabolic disorders)
Influence of health and healthcare disparities
Neurcognitive domains, measures, and normative data selected; methods of computing impairment and HAND diagnoses

4. Conclusions
CPE seems to be a valuable and meaningful metric for evaluating the quality of CART
neuropenetrance, and has been significantly linked to important pharmacological outcomes
in HIV+ individuals. CNS-penetrating antiretroviral regimens may reduce morbidity for
HIV+ individuals compared to regimens with low penetration. CSF viral replication is most
effectively controlled by ARV regimens with high CNS penetration, and treatment regimens
with a high CPE score are important to achieve CSF HIV-1 RNA suppression. Early and
consistent CART treatment can preserve or improve patients’ cognitive functioning, and
higher CPE regimens seem to be slightly more likely to provide these benefits compared to
lower CPE regimens.
There is some evidence that treatment regimens with higher CPE scores may be associated with modest, improved neurocognitive outcomes. Higher CPE score has been
associated with preserved or improved global neuropsychological functioning in a number
of studies, though not all. Several studies have also reported increased HAND diagnoses
among patients with lower CPE regimens. Global neurocognitive functioning has been
more thoroughly examined to date, and thus, these findings are given greater consideration.
Nonetheless, CPE is not as strongly or consistently associated with NP performance outcomes as many in the field initially hypothesized. There is mixed evidence for a relationship
with attention/working memory and learning/memory, but research has not consistently
supported a relationship between CPE and other neurocognitive domains when examined
specifically at the domain or individual test level. Studies that did find significant associations tended to use CPE 2010 score and/or employ more comprehensive and standardized
neuropsychological tests, which we discuss further as a direction for future research. This
is generally consistent with the conclusions drawn by Lin and colleagues [64]; in a review
of clinical treatment options and neuroHIV-targeted ARV treatment, the relationship between neurocognitive outcomes and CPE score was briefly summarized and found to be
inconsistent based on primarily observational studies.
The heterogeneity in the methods employed across studies complicates interpretations
in the literature. Studies include different CPE rankings (2008 vs. 2010) and may employ
them continuously or use categorical cut-offs that often differ across studies. Further complicating the picture, there are also changes that have occurred over time in antiretroviral
prescription practices. Increasingly over the last two decades, CART is more likely to be
started early on in the disease course when CD4 counts still remain high, integrase inhibitors are being used more commonly as first-line antiretroviral treatments, and, the most
recent rising interest in “single tablet regimens” (STR) and long-acting injectables [65–67].
These changes systematically affect CPE research over time; for instance, while CPE 2010
is more likely to be associated with neurocognitive outcomes, the newer CPE metric also
coincides temporally with important changes in ARV prescribing practices.
Studies also use a wide variety of different neuropsychological tests and normative
data, and may examine those data continuously or categorically. Few studies employed
comprehensive neuropsychological test batteries applying the best available normative
data, and even fewer have examined individual neuropsychological domains specifically.
The variety of normative data is further complicated by the variety of different countries in
which CPE research has been conducted.
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Importantly, research has not adequately investigated race/ethnicity in the context of
CPE. No study to date has explored whether or not CPE scores differ across racial/ethnic
groups and factors that may drive any potential discrepancies. This is especially pertinent
in the USA, where there are well-documented health disparities and systemic disadvantages among minoritized racial/ethnic groups in HIV [68,69]. Particularly, individuals
who identify as Black/African American and/or Hispanic/Latinx, minoritized groups
are not only disproportionately affected by HIV disease, but also receive poorer quality
HIV-related healthcare, including delayed treatment [70,71] and less access to HIV medications, particularly newer medications [72,73]. They also experience significantly higher
morbidity and mortality [74], including higher rates of neuropsychological impairment.
Yet this has not been investigated in the CPE literature, and in fact, many studies have not
adequately described the racial/ethnic background of their research study participants.
Future studies should ensure that the demographic characteristics of their sample are
fully described, including race/ethnicity, and should also investigate whether or not CPE
scores differ across racial/ethnic groups. This systematic bias may underlie some of the
inconsistent findings in the literature.
It is also difficult to disentangle the effects of CPE from other factors. The literature is
confounded by the fact that the populations investigated often have lengthy histories of past
ARV medication use prior to the current regimen. Extensive, suboptimal antiretroviral treatment (i.e., medications from the pre-CART era) may be particularly problematic. Therefore,
it is currently difficult to disentangle the effects of pre-CART medications from the question
of neuropenetrance. This remains a critical limitation of the current literature. Moreover,
when and why patients are placed on higher or lower CPE medications may systematically
differ, and these populations may be disproportionately sampled across studies. Studies
that focus on HIV+ individuals who have been treated exclusively with combined antiretroviral therapy regimens, especially individuals who have never experienced treatment
failure, are needed. For instance, randomized clinical trials assigning patients medication
based on CPE regimen will significantly differ from samples investigating patients with
worse functioning or adherence who have been switched to a different medication regimen,
which may differ from community samples of newly diagnosed HIV+ individuals. Therefore, the varied reasons why higher CPE medications are prescribed will likely complicate
all research in this area, especially cross-sectional research, although this may be attenuated
by clinical trials. In fact, others have highlighted the need for randomized clinical trials in
this area [64]. Additionally, the impact of comorbid neurological conditions, other medical
conditions, and immunological factors (e.g., cardiovascular disease, hepatitis co-infection,
CD4 counts) is difficult to quantify. In general, such conditions may also contribute to
worse neurological outcomes and vary across studies.
Treatment is, necessarily, individualized for HIV+ individuals, particularly in those
with advanced HIV disease. This is a complicating factor when comparing studies, but
there are some general conclusions that researchers have suggested for clinical practice. It
is important for HIV+ individuals to initiate CART early to increase the odds of preserving
long-term brain health. Providers and patients should also be aware that HIV+ individuals
may continue to develop neurocognitive impairment despite treatment with CART. Although medication decisions are necessarily the purview of physicians in terms of neurocognitive outcomes alone, research seems to suggest that higher CPE regimens may
better preserve neurocognitive functioning than lower CPE regimens, or may not have a
significant effect. Similarly, others have reported that the literature generally supports the
finding that higher CPE scores are associated with better CSF HIV viral suppression [64].
Based on this review, we recommend that studies employ the 2010 CPE ranking score,
which differentiates medications more finely across a wider range of CPE scores and provides rankings for a wider variety of medications. This, however, is a temporary solution;
since the last CPE update, more patients are being prescribed newer CART regimens with
medications that have not yet been assigned CPE scores, such as Dolutegravir, Bictegravir,
and Doravirine. As more of these patients are enrolled in research studies, it will preclude
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examining the relationship between these ARV medications and neuropenetrance in the
future. Therefore, a CPE ranking update is urgently needed, particularly as the CPE 2010
metric is now over a decade old.
We strongly recommend that studies examining neuropsychological/neurocognitive
functioning administer comprehensive neuropsychological batteries, in consultation with a
Clinical Neuropsychologist, whenever possible, especially batteries that have been wellvalidated in HIV+ individuals, such as those used in the CNS HIV Antiretroviral Therapy
Effects Research (CHARTER) and Multicenter AIDS Cohort Study (MACS) studies [20,75],
and apply the best available normative data [76,77]. In clinical settings, comprehensive
neuropsychological evaluations may not always be feasible, and in such cases, groups such
as the Mind Exchange Working Group [78] have discussed the strengths and limitations of
the available screening tools. Neurocognitive screening, at minimum, is now recommended
for all HIV+ patients, regardless of reported symptoms [43,78]. It is important to note, however, that screening tools often lack the sensitivity to identify less severe forms of HAND
and also lack the specificity of comprehensive, multi-domain batteries. Comprehensive
neuropsychological evaluation remains the criterion standard in the diagnosis of HAND.
Furthermore, it is useful if researchers examine neuropsychological functioning not
only at the global level but at the domain level as well; a more fine-grained analysis will
help inform whether or not some domains are preferentially impacted by less potent viral
inhibition, as there is already long-standing evidence that HIV-related neurodegeneration
compartmentalization may preferentially affect frontostriatal regions of the brain. We also
recommend that researchers consider continuous measures of CPE and NP, as categorical
cut-offs often differ between studies (i.e., median split) and may be somewhat arbitrary in
the larger context. Finally, they should be sure to describe the virological and demographic
characteristics of their sample, including race/ethnicity, and investigate the association
between CPE scores and these variables. Overall, these recommendations may improve the
generalizability of future research in this area and may contribute to our understanding of
HIV medication neuropenetrance and neurocognitive outcomes in HIV+ individuals.
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